Medication System
Antidopaminergics linked to worse cognitive, functional outcomes in HD at 6 years
Antidopaminergic medications were linked to worsening cognitive and functional effects that accelerate disease progression in Huntington’s disease, according to research presented at the Congress of the European Academy of Neurology.
Serotonin-based meds linked to lower risk of bleeding events 1 year post stroke
Treatment with selective serotonin/serotonin-norepinephrine reuptake inhibitors after ischemic stroke was associated with low risk of bleeding events at 1 year, according to a presenter at the International Stroke Conference.
20% of people with opioid use disorder get medication, study shows
In the United States, about one in five adults with opioid use disorder received medication as treatment in 2021, according to the results of research published in JAMA Network Open.
Lusaris Therapeutics launches with $60M to advance novel treatments for TRD, other neuro disorders
Lusaris Therapeutics announced its launch with $60 million in Series A financing to advance LSR-1019, a sublingual formulation of 5-MeO-DMT for patients with treatment-resistant depression and other severe neuropsychiatric disorders.
FDA approves oral treatment for adults with ADHD
Supernus Pharmaceuticals announced FDA approval of viloxazine extended-release capsules to treat ADHD in patients aged 18 years and older.